Hengrui Medicine Co., Ltd. (600276.SH): HRS-2430 Injection received the notification of approval for drug clinical trial.

Sinotimes Finance APP News, Hengrui Medicine (600276.SH) announced that the company has recently received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration (referred to as "NMPA") for HRS-2430 injection. The company will conduct clinical trials in the near future.